

# Maria Letizia Urban

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7819945/publications.pdf>

Version: 2024-02-01

57  
papers

1,532  
citations

304368

22  
h-index

329751

37  
g-index

58  
all docs

58  
docs citations

58  
times ranked

1887  
citing authors

#	ARTICLE	IF	CITATIONS
1	Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study. <i>Arthritis and Rheumatology</i> , 2022, 74, 295-306.	2.9	78
2	A unique circulating miRNA profile highlights thrombo-inflammation in Behçet's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 386-397.	0.5	17
3	Clinical Delphi on aPL Negativization: Report from the APS Study Group of the Italian Society for Rheumatology (SIR-APS). <i>Thrombosis and Haemostasis</i> , 2022, 122, 1612-1620.	1.8	0
4	Validity of Machine Learning in Predicting Giant Cell Arteritis Flare After Glucocorticoids Tapering. <i>Frontiers in Immunology</i> , 2022, 13, 860877.	2.2	9
5	Use of Biologics to Treat Relapsing and/or Refractory Eosinophilic Granulomatosis With Polyangiitis: Data From a European Collaborative Study. <i>Arthritis and Rheumatology</i> , 2021, 73, 498-503.	2.9	55
6	Pharmacological Interventions for the Prevention of Fetal Growth Restriction: A Systematic Review and Network Meta-Analysis. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 189-199.	2.3	7
7	Cardiac involvement in eosinophilic granulomatosis with polyangiitis (formerly Churg-Strauss) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T <i>Medicine</i> , 2021, 85, 68-79.	1.0	14
8	Risk of acute arterial and venous thromboembolic events in eosinophilic granulomatosis with polyangiitis (Churg's syndrome). <i>European Respiratory Journal</i> , 2021, 57, 2004158.	3.1	19
9	FC 039RENAL OUTCOME AFTER RITUXIMAB IN ADULT-ONSET IGA VASCULITIS AND CRESCENTIC IGA NEPHROPATHY: A MULTICENTRE STUDY. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.4	2
10	Neutrophil-mediated mechanisms of damage and <i>in-vitro</i> protective effect of colchicine in non-vascular Behçet's syndrome. <i>Clinical and Experimental Immunology</i> , 2021, 206, 410-421.	1.1	24
11	Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLISS-LN). Results from a large, nationwide, multicentric cohort. <i>Journal of Autoimmunity</i> , 2021, 124, 102729.	3.0	23
12	Comparison of treatments for the prevention of fetal growth restriction in obstetric antiphospholipid syndrome: a systematic review and network meta-analysis. <i>Internal and Emergency Medicine</i> , 2021, 16, 1357-1367.	1.0	7
13	Prevalence and clinical course of SARS-CoV-2 infection in patients with Behçet's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 132, 47-50.	0.4	4
14	Prevalence and clinical course of SARS-CoV-2 infection in patients with Behçet's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 47-50.	0.4	7
15	Rituximab for chronic periaortitis without evidence of IgG4-related disease: a long-term follow-up study of 20 patients. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 433-434.	0.5	19
16	Intravenous immunoglobulin for the secondary prevention of stillbirth in obstetric antiphospholipid syndrome: A case series and systematic review of literature. <i>Autoimmunity Reviews</i> , 2020, 19, 102620.	2.5	8
17	P0181PERSISTENT C3 HYPOCOMPLEMENTEMIA AND MODERATE TUBULOINTERSTITIAL SCARRING AS EARLY PREDICTORS OF END-STAGE RENAL DISEASE IN LUPUS NEPHRITIS. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.4	0
18	P0280ENVIRONMENTAL AND OCCUPATIONAL EXPOSURES IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS. A CASE-CONTROL STUDY. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.4	0

#	ARTICLE	IF	CITATIONS
19	Long-term effectiveness and safety of secukinumab for treatment of refractory mucosal and articular Behçet's phenotype: a multicentre study. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1098-1104.	0.5	39
20	SARS-CoV-2 infection among patients with systemic autoimmune diseases. <i>Autoimmunity Reviews</i> , 2020, 19, 102575.	2.5	131
21	Obstetric antiphospholipid syndrome is not associated with an increased risk of subclinical atherosclerosis. <i>Rheumatology</i> , 2020, 59, 3709-3716.	0.9	12
22	FCGR3B polymorphism predicts relapse risk in eosinophilic granulomatosis with polyangiitis. <i>Rheumatology</i> , 2020, 59, 3563-3566.	0.9	8
23	Adalimumab effectively controls both anterior and posterior noninfectious uveitis associated with systemic inflammatory diseases: focus on Behçet's syndrome. <i>Inflammopharmacology</i> , 2020, 28, 711-718.	1.9	19
24	Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life Setting. <i>Arthritis and Rheumatology</i> , 2020, 72, 1314-1324.	2.9	58
25	FP165 SLOWLY PROGRESSIVE ANCA-ASSOCIATED GLOMERULONEPHRITIS: A MULTICENTRE STUDY. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.4	0
26	298. RITUXIMAB FOR DIFFICULT-TO-TREAT CHRONIC PERIAORTITIS: A CASE-SERIES OF 20 PATIENTS. <i>Rheumatology</i> , 2019, 58, .	0.9	0
27	Fibrocytes in Chronic Periaortitis: A Novel Mechanism Linking Inflammation and Fibrosis. <i>Arthritis and Rheumatology</i> , 2019, 71, 1913-1922.	2.9	17
28	135. ATHERO-THROMBOTIC AND VENOUS EVENTS (AVTE) IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA): A MULTICENTRE STUDY OF 573 ITALIAN PATIENTS. <i>Rheumatology</i> , 2019, 58, .	0.9	0
29	Rituximab as Maintenance Treatment for Systemic Lupus Erythematosus: A Multicenter Observational Study of 147 Patients. <i>Arthritis and Rheumatology</i> , 2019, 71, 1670-1680.	2.9	22
30	Unveiling the Efficacy, Safety, and Tolerability of Anti-Interleukin-1 Treatment in Monogenic and Multifactorial Autoinflammatory Diseases. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1898.	1.8	60
31	Clinical and Prognostic Significance of Serum IgG4 in Chronic Periaortitis. An Analysis of 113 Patients. <i>Frontiers in Immunology</i> , 2019, 10, 693.	2.2	22
32	117. PREDICTION OF LONG-TERM EVOLUTIONARY PROFILES IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (CHURG-STRAUSS) BASED ON BASELINE AND FOLLOW-UP CHARACTERISTICS. <i>Rheumatology</i> , 2019, 58, .	0.9	0
33	FRI0199...EFFECTIVENESS AND SAFETY OF BELIMUMAB IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM A LARGE, NATIONWIDE, MULTICENTRIC STUDY. , 2019, , .		1
34	Scheduled rituximab maintenance reduces relapse rate in eosinophilic granulomatosis with polyangiitis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrheumdis-2017-211897.	0.5	32
35	Changing patterns in clinical-histological presentation and renal outcome over the last five decades in a cohort of 499 patients with lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1318-1325.	0.5	119
36	Brief Report: Rituximab for the Treatment of Adult-Onset IgA Vasculitis (Henoch-Schönlein). <i>Arthritis and Rheumatology</i> , 2018, 70, 109-114.	2.9	71

#	ARTICLE	IF	CITATIONS
37	A large-scale genetic analysis reveals an autoimmune origin of idiopathic retroperitoneal fibrosis. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 1662-1665.	1.5	17
38	SaO020RITUXIMAB AS MAINTENANCE THERAPY FOR SYSTEMIC LUPUS ERYTHEMATOSUS. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i323-i323.	0.4	0
39	Secukinumab reduces plasma oxidative stress in psoriasis: A case-based experience. <i>Dermatologic Therapy</i> , 2018, 31, e12675.	0.8	6
40	Use of Interleukin-1 Blockers in Pericardial and Cardiovascular Diseases. <i>Current Cardiology Reports</i> , 2018, 20, 61.	1.3	29
41	Complement blockade in ANCA-associated vasculitis: an index case, current concepts and future perspectives. <i>Internal and Emergency Medicine</i> , 2017, 12, 727-731.	1.0	29
42	Repeated low-dose courses of rituximab in SLE-associated antiphospholipid syndrome: Data from a tertiary dedicated centre. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 46, e21-e23.	1.6	15
43	Idiopathic Mediastinal Fibrosis: a Systemic Immune-Mediated Disorder. A Case Series and a Review of the Literature. <i>Clinical Reviews in Allergy and Immunology</i> , 2017, 52, 446-459.	2.9	36
44	Adalimumab effectiveness in Behçet's disease: short and long-term data from a multicenter retrospective observational study. <i>Clinical Rheumatology</i> , 2017, 36, 451-455.	1.0	52
45	MP204SLOWLY PROGRESSIVE GLOMERULONEPHRITIS IN PATIENTS WITH ANCA ASSOCIATED VASCULITIS (AAV). <i>Nephrology Dialysis Transplantation</i> , 2017, 32, iii502-iii503.	0.4	0
46	Methotrexate versus cyclophosphamide for remission maintenance in ANCA-associated vasculitis: A randomised trial. <i>PLoS ONE</i> , 2017, 12, e0185880.	1.1	37
47	Cutaneous sarcoidosis during rituximab treatment for microscopic polyangiitis: an uncommon adverse effect?. <i>European Journal of Dermatology</i> , 2017, 27, 667-668.	0.3	8
48	Fcγ3-receptor 3B ( FCGR3B ) copy number variations in patients with eosinophilic granulomatosis with polyangiitis. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 1597-1599.e8.	1.5	18
49	SP137PERSISTENT REDUCTION OF SERUM C3 AND LUPUS NEPHRITIS OUTCOME: A RETROSPECTIVE OBSERVATIONAL STUDY. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iii422-iii423.	0.4	1
50	Idiopathic and secondary forms of retroperitoneal fibrosis: A diagnostic approach. <i>Revue De Medecine Interne</i> , 2015, 36, 15-21.	0.6	71
51	Chronic periaortitis with thoracic aorta and epiaortic artery involvement: a systemic large vessel vasculitis?. <i>Rheumatology</i> , 2015, 54, 2004-2009.	0.9	32
52	Association of Serum C3 Concentration and Histologic Signs of Thrombotic Microangiopathy with Outcomes among Patients with ANCA-Associated Renal Vasculitis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 2143-2151.	2.2	67
53	Association between idiopathic retroperitoneal fibrosis and autoimmune thyroiditis: A case-control study. <i>Autoimmunity Reviews</i> , 2015, 14, 16-22.	2.5	36
54	Asbestos and Smoking as Risk Factors for Idiopathic Retroperitoneal Fibrosis. <i>Annals of Internal Medicine</i> , 2014, 161, 181.	2.0	64

#	ARTICLE	IF	CITATIONS
55	Treatment of idiopathic retroperitoneal fibrosis. <i>Expert Opinion on Orphan Drugs</i> , 2014, 2, 769-777.	0.5	1
56	Methotrexate plus prednisone in patients with relapsing idiopathic retroperitoneal fibrosis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1584-1586.	0.5	56
57	Rituximab therapy for chronic periaortitis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1262-1264.	0.5	53